Mgc Pharmaceuticals Share Discussion Threads

[hoder] 05/10/2022 17:58

Wow so quick to get a vote. LMAO

a 93% OK with share dilution.


Sounds like a Mugabe or Saddam type of voting. Even Putin can not do that in one day.

Guaranteed it's not that figures.

It's even illegal very likely

[heatseek77] 05/10/2022 14:09

Thought the sloppy alias had sold out?🤷

[amaretto1] 05/10/2022 13:05

Another 5.5 million just voted for !!

[sloppyjoe2] 04/10/2022 21:18

"Let Mercer issue 5-10bn shares, don't worry, at end of the day, Pfizer will pick at 150p-200p per shares. £15bn take out, ganja medicine is big" Mate: a/ wtf have you been smoking, and b/ can I please get some?

[heatseek77] 04/10/2022 16:26

Decent new appointment, decent CV unlike our uneducated oink (fag tip) on the other thread - so common, so vulgar

[monster500] 04/10/2022 07:48

You have allot to say (de ramping) considering you have no position here. Lol

[halland75] 04/10/2022 07:41

Beware of Amarepoo, the laughing stock of ADVFN.
Top Loser who has lost big in...

AGL.
STX.
ENET.
And goodness knows where else!

The mad plucker also thinks he is a member of The Mafia 😂😂😂😂8514;

You were warned!

[amaretto1] 04/10/2022 07:21

My opinion... they are running out of cash.....They have a big problem..Share holders are dumping stock .. MM have no buyers for it ..All linked to the finance structure....Imo this as been a total scam !! UK Investors been led in by ???I've no position here ... but I'm watching the car crash unfold

[zxie] 04/10/2022 07:11

Looking forward

[amaretto1] 04/10/2022 07:09

Another RNS ....Companies in trouble ! U don't take them on board for nothing ..

[looneytune] 04/10/2022 07:07

All positive!
04/10/2022 7:00am
UK Regulatory (RNS & others)

TIDMMXC

RNS Number : 6899B

MGC Pharmaceuticals Limited

04 October 2022

MGC Pharmaceuticals Ltd.

Appointment of UK Advisor, Hannam & Partners, and Company Update

4 October 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce the formal appointment of UK capital markets advisor, Hannam & Partners, as financial and corporate advisors to the Company, with immediate effect ( ).

Hannam & Partners are a highly regarded UK advisory firm with a long track record in UK capital markets, and more recently in the UK and EU cannabis sector.

The Board believes that this appointment, along with delivery on the commercial contracts and production plans currently in place, will greatly enhance the Company's ability to maximise its enterprise value for all shareholders in the future.

Appointment of new COO/Deputy CEO

The Company advises that it has appointed Ms Yifat Steuer as the Company's new Chief Operating Officer/Deputy CEO, with Ms Steuer having been previously engaged as an advisor to the executive team during 2022.

Ms Steuer has over 20 years of experience as an executive, working across a range of pharmaceutical companies including Johnson & Johnson and GlaxoSmithKline, as well experience working with SMEs and start-ups.

Ms Steuer is a qualified Chartered Accountant and holds an MBA degree from Bayes Business School - University of London. Ms Steuer will work closely with CEO Roby Zomer to execute on MGC Pharma's business strategy, utilising her experience in in pharmaceuticals, manufacturing, logistics, medical technology and digital health.

Chairman role change

The Company also advises that Mr Brett Mitchell's role as Chairman of the Company's board of directors has transitioned from an executive to a non-executive position, to be more in line with corporate structuring of UK listed companies. Mr Mitchell will continue to provide corporate and capital markets advisory services to the Company through an existing consultancy agreement between MGC Pharma and Mr Mitchell's private consulting company, as disclosed in the Company's recent 2022 Annual Report.

Investor Update - 11(th) October

Following the release of our 2022 Annual Report, the company is pleased to announce that it will be providing a live presentation via the Investor Meet Company platform on 11th Oct 2022 at 11:00am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can register with Investor Meet Company for free and add to meet MGC PHARMACEUTICALS LIMITED via:



Investors who already follow MGC PHARMACEUTICALS LIMITED on the Investor Meet Company platform will automatically be invited.

--Ends--

Authorised for release by the Chairman, for further information please contact:

[hoder] 03/10/2022 13:07

Ponzi scheme, by Segev. So that must the other expenses, but what are they?


Mr Nativ Segev, Non‐Executive Director ‐ Current Director Agreement
 Director Agreement dated 1 July 2020, no termination date or payment on termination;
o Standard director fee of $4,000 per month
 MGC Pharmaceuticals d.o.o (the Group’s Slovenian subsidiary) director agreement commenced 1 July
2021; no termination date or payment on termination;
o Fees of €1,024 per month (excluding taxes)
Services Agreement with Brighght Global Limited, an entity controlled by Mr Segev, valid from 1 July 2020 to
current
 MGC Pharmaceuticals Ltd services agreement automatically renews every 12 months unless
terminated, 90 days’ notice;
o Fees of $5,000 per month
o No termination fee payabl

[the infidel] 03/10/2022 13:04

Any further drawdown of funds under the second agreement is at the investor’s discretion, and the
Company having sufficient capacity under Chapter 7 of the ASX Listing Rulesto issue the convertible notes,
or shareholder approval being obtained. The Group is seeking shareholder approval at a General Meeting
on 5 October 2022 to issue up to a further US$5,500,000 in convertible notes under the second
agreement.

[amaretto1] 03/10/2022 08:41

Results are showing cracks !

[heatseek77] 29/9/2022 07:33

Morning ya ugly lonely 🥚
Really posting every other minute 😂🤣


The recent RNS clearly issue now resolved

MGC Pharma has cooperated fully with the TGA to remedy the issues raised, including removing all posts of concern from its social media channels, some of which were third-party posts, and placing the Company's website into maintenance. The website will be live again in November following a rebranding exercise, with new internal guidelines implemented to prevent a repeat occurrence.